Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $1.31 billion. The enterprise value is $1.85 billion.
Important Dates
The next estimated earnings date is Thursday, February 20, 2025, after market close.
| Earnings Date | Feb 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 115.03 million shares outstanding. The number of shares has increased by 6.04% in one year.
| Current Share Class | 115.03M |
| Shares Outstanding | 115.03M |
| Shares Change (YoY) | +6.04% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 1.07% |
| Owned by Institutions (%) | 107.00% |
| Float | 105.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.85 |
| PS Ratio | 0.53 |
| Forward PS | 0.46 |
| PB Ratio | 1.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.17 |
| P/OCF Ratio | 9.77 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.06, with an EV/FCF ratio of 19.98.
| EV / Earnings | n/a |
| EV / Sales | 0.75 |
| EV / EBITDA | 15.06 |
| EV / EBIT | 61.39 |
| EV / FCF | 19.98 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.04 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 4.74 |
| Debt / FCF | 6.86 |
| Interest Coverage | 1.00 |
Financial Efficiency
Return on equity (ROE) is -5.78% and return on invested capital (ROIC) is 1.00%.
| Return on Equity (ROE) | -5.78% |
| Return on Assets (ROA) | 0.73% |
| Return on Capital (ROIC) | 1.00% |
| Revenue Per Employee | $524,309 |
| Profits Per Employee | -$22,177 |
| Employee Count | 4,700 |
| Asset Turnover | 0.95 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -14.95M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.12% in the last 52 weeks. The beta is 1.43, so Evolent Health's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | -63.12% |
| 50-Day Moving Average | 16.94 |
| 200-Day Moving Average | 24.05 |
| Relative Strength Index (RSI) | 36.51 |
| Average Volume (20 Days) | 2,771,494 |
Short Selling Information
The latest short interest is 10.51 million, so 9.13% of the outstanding shares have been sold short.
| Short Interest | 10.51M |
| Short Previous Month | 12.49M |
| Short % of Shares Out | 9.13% |
| Short % of Float | 9.98% |
| Short Ratio (days to cover) | 3.10 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.46 billion and -$104.23 million in losses. Loss per share was -$0.91.
| Revenue | 2.46B |
| Gross Profit | 393.27M |
| Operating Income | 30.15M |
| Pretax Income | -88.91M |
| Net Income | -104.23M |
| EBITDA | 122.93M |
| EBIT | 30.15M |
| Loss Per Share | -$0.91 |
Full Income StatementBalance Sheet
The company has $96.58 million in cash and $635.21 million in debt, giving a net cash position of -$538.62 million or -$4.68 per share.
| Cash & Cash Equivalents | 96.58M |
| Total Debt | 635.21M |
| Net Cash | -538.62M |
| Net Cash Per Share | -$4.68 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 9.03 |
| Working Capital | 20.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $134.38 million and capital expenditures -$41.74 million, giving a free cash flow of $92.64 million.
| Operating Cash Flow | 134.38M |
| Capital Expenditures | -41.74M |
| Free Cash Flow | 92.64M |
| FCF Per Share | $0.81 |
Full Cash Flow StatementMargins
Gross margin is 15.96%, with operating and profit margins of 1.22% and -2.93%.
| Gross Margin | 15.96% |
| Operating Margin | 1.22% |
| Pretax Margin | -3.54% |
| Profit Margin | -2.93% |
| EBITDA Margin | 4.99% |
| EBIT Margin | 1.22% |
| FCF Margin | 3.76% |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.04% |
| Shareholder Yield | -6.04% |
| Earnings Yield | -7.94% |
| FCF Yield | 7.06% |
Dividend DetailsAnalyst Forecast
The average price target for Evolent Health is $25.90, which is 126.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.90 |
| Price Target Difference | 126.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 13.71% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 2.11 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.11 |
| Piotroski F-Score | 6 |